BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

BIOGEN INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$233.48+0.83 (+0.36%)

Close on Oct 19, 2026

Market cap: $34.72B
P/E (TTM): 41.3
Dividend yield: –

BIOGEN INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31
Revenue	9,891	9,676	9,836	10,173	10,982	13,445	14,378	13,453	12,274	11,449	10,764	9,703	6,932	5,516	5,049	4,716	4,377	4,098	3,172
Cost of Revenue	2,404	2,310	2,533	2,278	2,110	1,805	1,955	1,816	1,630	1,479	1,240	1,171	858	545	467	400	382	402	335
Gross Profit	7,486	7,366	7,302	7,895	8,872	11,639	12,423	11,637	10,644	9,970	9,523	8,532	6,075	4,971	4,582	4,316	3,995	3,696	2,836
Research & Development	1,779	1,980	2,445	2,231	2,501	3,991	2,281	2,597	2,254	1,973	2,013	1,893	1,444	1,335	1,220	1,249	1,283	1,072	925
Selling, General & Admin	2,434	2,404	2,550	2,404	2,674	2,505	2,375	2,106	1,934	1,947	2,113	2,232	1,712	1,277	1,056	1,032	911	925	776
Advertising Expenses	72	67	71	54	99	112	79	90	75	106	109	93	73	54	45	35	27	–	–
Total Costs & Expenses	8,334	7,770	8,539	6,582	9,237	8,397	7,335	7,564	6,928	6,297	5,873	5,748	4,442	3,707	3,324	3,468	3,082	2,884	2,392
Operating Income	–	–	–	–	2,841	4,550	7,043	5,889	5,346	5,152	4,891	3,972	2,516	1,856	1,725	1,249	1,295	1,214	780
Interest Expense	268	250	247	247	254	223	187	201	251	260	96	30	32	37	33	36	36	52	–
Interest & Investment Income	125	68	277	89	11	42	120	113	79	63	22	12	8.20	30	19	22	49	72	–
Income from Equity Investments	–	0	0	2.60	35	3.30	-77	0	0	0	-13	-15	-17	-4.52	0	0	–	–	–
Other Non-Operating Income	-306	-344	-316	108	-1,096	497	83	11	-217	-219	-124	-26	-35	-0.74	-13	-19	37	-58	72
Merger & Restructuring Charges	49	30	219	131	0	0	1.50	12	0.90	33	93	0	0	2.23	19	75	–	–	–
Asset Impairment Charges	0	0	0	0	0	–	–	–	–	–	–	–	–	0	0	–	–	–	–
Gain (Loss) on Investments	20	100	291	277	825	-686	205	120	-36	6.00	-3.80	12	22	11	19	14	24	-1.08	-17
Gain (Loss) on Sale of Assets	–	0	0	504	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–
Legal Settlements	-140	-26	-3.90	-917	0	0	–	0	0	-455	0	0	–	–	–	–	–	–	–
Pretax Income	1,557	1,906	1,297	3,592	1,745	5,048	7,126	5,900	5,129	4,933	4,767	3,947	2,481	1,855	1,711	1,230	1,333	1,156	852
Income Tax Expense	264	274	135	633	53	992	1,158	1,426	2,459	1,237	1,162	990	601	471	445	331	356	366	272
Net Income incl. Noncontrolling Interests	1,293	1,632	1,162	2,962	1,728	4,061	5,889	4,474	2,670	3,696	3,593	2,942	1,862	1,380	1,267	899	977	790	580
Minority Interest in Earnings	0	0	0.40	-85	172	60	0	43	131	-7.10	46	6.80	0	0	32	-107	6.93	6.94	-58
Net Income	1,293	1,632	1,161	3,047	1,556	4,001	5,889	4,431	2,539	3,703	3,547	2,935	1,862	1,380	1,234	1,005	970	783	638
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	–	1,862	1,380	1,234	1,003	968	782	–
EPS (Basic)(per share)	8.83	11.21	8.02	20.96	10.44	24.86	31.47	21.63	11.94	16.96	15.38	12.42	7.86	5.80	5.09	3.98	3.37	2.67	2.02
EPS (Diluted)(per share)	8.79	11.18	7.97	20.87	10.40	24.80	31.42	21.58	11.92	16.93	15.34	12.37	7.81	5.76	5.04	3.94	3.35	2.65	1.99
Shares Outstanding (Basic, Weighted)(shares)	147	146	145	145	149	161	187	205	213	218	231	236	237	238	242	252	287	292	316
Shares Outstanding (Diluted, Weighted)(shares)	147	146	146	146	150	161	187	205	213	219	231	237	238	240	245	255	289	295	320
EBITDA	–	–	–	–	3,328	5,007	7,507	6,539	6,427	5,834	5,491	4,661	3,047	2,221	2,084	1,605	1,723	1,676	1,160

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 74.0%
Operating margin: –
Net margin: 8.3%
Return on equity, FY2025: –

Financial strength

Current ratio: 1.87
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 32.8%

Valuation

P/E ratio: 41.3
Price to sales: 3.46
Price to book: –
Dividend yield: –